PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer

Bairavi Shankar, Jarushka Naidoo

Abstract

Immune checkpoint inhibitors (ICIs) utilize the natural programming of the immune system to initiate an antitumor response, counteracting checkpoint molecule expression on tumor cells (1).